NADPH oxidase-induced NALP3 inflammasome activation is driven by thioredoxin-interacting protein which contributes to podocyte injury in hyperglycemia

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Gao, Pan ^a   He, Fang Fang ^a   Tang, Hui ^a   Lei, Chun Tao ^a   Chen, Shan ^a   Meng, Xian Fang ^b   Su, Hua ^a   Zhang, Chun ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; THIOREDOXIN INTERACTING PROTEIN; CARRIER PROTEIN; CIAS1 PROTEIN, MOUSE; INTERLEUKIN 1BETA CONVERTING ENZYME; NLRP3 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOREDOXIN; TXNIP PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DAMAGE; CELL PROTECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; ENZYME INHIBITION; HYPERGLYCEMIA; MOUSE; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; BIOPSY; C57BL MOUSE; ENZYMOLOGY; FLUORESCENCE MICROSCOPY; GENE DELETION; GLOMERULUS; HUMAN; INFLAMMATION; KIDNEY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BIOPSY; CARRIER PROTEINS; CASPASE 1; GENE DELETION; HUMANS; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-1BETA; KIDNEY; KIDNEY GLOMERULUS; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; NADPH OXIDASE; PODOCYTES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; THIOREDOXINS;

EID: 84925321755     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/504761     Document Type: Article

References (49)

1. M. Brownlee, "Biochemistry and molecular cell biology of diabetic complications," Nature, vol. 414, no. 6865, pp. 813-820, 2001.
2. U. Sen, P. Basu, O. A. Abe et al., "Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure," The American Journal of Physiology-Renal Physiology, vol. 297, no. 2, pp. F410-F419, 2009.
3. F.-F. He, C. Zhang, S. Chen et al., "Role of CD2-associated protein in albumin overload-induced apoptosis in podocytes," Cell Biology International, vol. 35, no. 8, pp. 827-834, 2011.
4. K. Susztak, A. C. Raff, M. Schiffer, and E.P. Böttinger, "Glucoseinduced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy," Diabetes, vol. 55, no. 1, pp. 225-233, 2006.
5. M. W. Steffes, D. Schmidt, R. McCrery et al., "Glomerular cell number in normal subjects and in type 1 diabetic patients," Kidney International, vol. 59, no. 6, pp. 2104-2113, 2001.
6. G. Ren, C. Huynh, K. Bijian, and A. V. Cybulsky, "Role of apoptosis signal-regulating kinase 1 in complement-mediated glomerular epithelial cell injury," Molecular Immunology, vol. 45, no. 8, pp. 2236-2246, 2008.
7. F. Yi, M. Xia, N. Li, C. Zhang, L. Tang, and P.-L. Li, "Contribution of guanine nucleotide exchange factor Vav2 to hyperhomocysteinemic glomerulosclerosis in rats," Hypertension, vol. 53, no. 1, pp. 90-96, 2009.
8. C. Zhang, J.-J. Hu, M. Xia, K. M. Boini, C. Brimson, and P.-L. Li, "Redox signaling via lipid raft clustering in homocysteineinduced injury of podocytes," Biochimica et Biophysica Acta, vol. 1803, no. 4, pp. 482-491, 2010.
9. C. Zhang, J. J. Hu, M. Xia et al., "Protection of podocytes from hyperhomocysteinemia-induced injury by deletion of the gp91phox gene," Free Radical Biology and Medicine, vol. 48, no. 8, pp. 1109-1117, 2010.
10. S.C. Eisenbarth, O. R. Colegio, W. O'Connor Jr., F. S. Sutterwala, and R. A. Flavell, "Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants," Nature, vol. 453, no. 7198, pp. 1122-1126, 2008.
11. J. M. Kahlenberg and G. R. Dubyak, "Differing caspase-1 activation states in monocyte versus macrophage models of IL- 1β processing and release," Journal of Leukocyte Biology, vol. 76, no. 3, pp. 676-684, 2004.
12. S. L. Cassel, S. C. Eisenbarth, S. S. Iyer et al., "The Nalp3 inflammasome is essential for the development of silicosis," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 26, pp. 9035-9040, 2008.
13. C. Zhang, K. M. Boini, M. Xia et al., "Activation of Nodlike receptor protein 3 inflammasomes turns on podocyte injury and glomerular sclerosis in hyperhomocysteinemia," Hypertension, vol. 60, no. 1, pp. 154-162, 2012.
14. S. Mariathasan, D. S. Weiss, K. Newton et al., "Cryopyrin activates the inflammasome in response to toxins and ATP," Nature, vol. 440, no. 7081, pp. 228-232, 2006.
15. S. Malozowski and J. T. Sahlroot, "Interleukin-1-receptor antagonist in type 2 diabetes mellitus," The New England Journal of Medicine, vol. 357, no. 3, pp. 302-303, 2007.
16. R. Zhou, A. Tardivel, B. Thorens, I. Choi, and J. Tschopp, "Thioredoxin-interacting protein links oxidative stress to inflammasome activation," Nature Immunology, vol. 11, no. 2, pp. 136-140, 2010.
17. F. Meissner, K. Molawi, and A. Zychlinsky, "Superoxide dismutase 1 regulates caspase-1 and endotoxic shock," Nature Immunology, vol. 9, no. 8, pp. 866-872, 2008.
18. S. L. Demento, S. C. Eisenbarth, H. G. Foellmer et al., "Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy," Vaccine, vol. 27, no. 23, pp. 3013-3021, 2009.
19. J. M. Abais, C. Zhang, M. Xia et al., "NADPHoxidase-mediated triggering of inflammasome activation in mouse podocytes and glomeruli during hyperhomocysteinemia," Antioxidants and Redox Signaling, vol. 18, no. 13, pp. 1537-1548, 2013.
20. R. Zhou, A. S. Yazdi, P. Menu, and J. Tschopp, "A role for mitochondria in NLRP3 inflammasome activation," Nature, vol. 469, no. 7329, pp. 221-225, 2011.
21. J. B. Johnston, J. W. Barrett, S. H. Nazarian et al., "A poxvirusencoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection," Immunity, vol. 23, no. 6, pp. 587-598, 2005.
22. C. M. Oslowski, T. Hara, B. O'Sullivan-Murphy et al., "Thioredoxin-interacting protein mediates ER stress-induced β cell death through initiation of the inflammasome," Cell Metabolism, vol. 16, no. 2, pp. 265-273, 2012.
23. L. Franchi, T. Eigenbrod, and G. Núñez, "Cutting edge: TNF- α mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation," Journal of Immunology, vol. 183, no. 2, pp. 792-796, 2009.
24. A. M. Kaimul, H. Nakamura, H. Masutani, and J. Yodoi, "Thioredoxin and thioredoxin-binding protein-2 in cancer and metabolic syndrome," Free Radical Biology and Medicine, vol. 43, no. 6, pp. 861-868, 2007.
25. K. Schroder, R. Zhou, and J. Tschopp, "The NLRP3 inflammasome: a sensor formetabolic danger?" Science, vol. 327, no. 5963, pp. 296-300, 2010.
26. B.-C. Liu, X. Song, X.-Y. Lu et al., "High glucose induces podocyte apoptosis by stimulating TRPC6 via elevation of reactive oxygen species," Biochimica et Biophysica Acta, vol. 1833, no. 6, pp. 1434-1442, 2013.
27. P. Gao, X. F. Meng, H. Su et al., "Thioredoxin-interacting protein mediates NALP3 inflammasome activation in podocytes during diabetic nephropathy," Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1843, no. 11, pp. 2448-2460, 2014.
28. S. Faubel, D. Ljubanovic, L. Reznikov, H. Somerset, C. A. Dinarello, and C. L. Edelstein, "Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis," Kidney International, vol. 66, no. 6, pp. 2202-2213, 2004.
29. A. Vilaysane, J. Chun, M. E. Seamone et al., "The NLRP3 inflammasome promotes renal inflammation and contributes to CKD," Journal of the American Society of Nephrology, vol. 21, no. 10, pp. 1732-1744, 2010.
30. J. Zhao, H. Wang, C. Dai et al., "P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ASC/Caspase 1 pathway," Arthritis and Rheumatism, vol. 65, no. 12, pp. 3176-3185, 2013.
31. K.-F. Hua, S.-M. Yang, T.-Y. Kao et al., "Osthole mitigates progressive IgA nephropathy by inhibiting reactive oxygen species generation and NF-kappaB/NLRP3 pathway," PLoS ONE, vol. 8, no. 10, Article ID e77794, 2013.
32. R. Scarpioni, D. Rigante, L. Cantarini et al., "Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1β monoclonal antibody canakinumab," Clinical Rheumatology, 2014.
33. J. Tschopp and K. Schroder, "NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?" Nature Reviews Immunology, vol. 10, no. 3, pp. 210-215, 2010.
34. F. Giacco and M. Brownlee, "Oxidative stress and diabetic complications," Circulation Research, vol. 107, no. 9, pp. 1058-1070, 2010.
35. J. M. Forbes, M. T. Coughlan, and M. E. Cooper, "Oxidative stress as amajor culprit in kidney disease in diabetes," Diabetes, vol. 57, no. 6, pp. 1446-1454, 2008.
36. Y. Gorin, K. Block, J. Hernandez et al., "Nox4NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney," The Journal of Biological Chemistry, vol. 280, no. 47, pp. 39616-39626, 2005.
37. S. Yamagishi, "Comment on:Thallas-Bonke et al. (2008) 'Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway', Diabetes, vol. 57, pp. 460-469, 2008," Diabetes, vol. 57, no. 6, pp. e13-e14, 2008.
38. S. Ruiz, P. E. Pergola, R. A. Zager, and N. D. Vaziri, "Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease," Kidney International, vol. 83, no. 6, pp. 1029-1041, 2013.
39. S. S. Gill and N. Tuteja, "Reactive oxygen species and antioxidantmachinery in abiotic stress tolerance in crop plants," Plant Physiology and Biochemistry, vol. 48, no. 12, pp. 909-930, 2010.
40. Y. Meyer, B. B. Buchanan, F. Vignols, and J.-P. Reichheld, "Thioredoxins and glutaredoxins: unifying elements in redox biology," Annual Review of Genetics, vol. 43, pp. 335-367, 2009.
41. D. F. D. Mahmood, A. Abderrazak, K. El Hadri, T. Simmet, and M. Rouis, "The thioredoxin system as a therapeutic target in human health and disease," Antioxidants and Redox Signaling, vol. 19, no. 11, pp. 1266-1303, 2013.
42. K.-S. Chen and H. F. DeLuca, "Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3," Biochimica et Biophysica Acta, vol. 1219, no. 1, pp. 26-32, 1994.
43. E. Junn, S. H. Han, J. Y. Imet al., "Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function," Journal of Immunology, vol. 164, no. 12, pp. 6287-6295, 2000.
44. 3 upregulated protein 1 (VDUP1) is a regulator for redox signaling and stress-mediated diseases," The Journal of Dermatology, vol. 33, no. 10, pp. 662-669, 2006.
45. P. C. Schulze, J. Yoshioka, T. Takahashi, Z. He, G. L. King, and R. T. Lee, "Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein," The Journal of Biological Chemistry, vol. 279, no. 29, pp. 30369-30374, 2004.
46. X. Li, Y. Rong, M. Zhang et al., "Up-regulation of thioredoxin interacting protein (Txnip) by p38 MAPK and FOXO1 contributes to the impaired thioredoxin activity and increased ROS in glucose-treated endothelial cells," Biochemical and Biophysical Research Communications, vol. 381, no. 4, pp. 660-665, 2009.
47. A. Advani, R. E. Gilbert, K. Thai et al., "Expression, localization, and function of the thioredoxin system in diabetic nephropathy," Journal of the American Society of Nephrology, vol. 20, no. 4, pp. 730-741, 2009.
48. Y. Hamada and M. Fukagawa, "A possible role of thioredoxin interacting protein in the pathogenesis of streptozotocin induced diabetic nephropathy," Kobe Journal of Medical Sciences, vol. 53, no. 1-2, pp. 53-61, 2007.
49. T. Kobayashi, S. Uehara, T. Ikeda, H. Itadani, and H. Kotani, "Vitamin D3 up-regulated protein-1 regulates collagen expression in mesangial cells," Kidney International, vol. 64, no. 5, pp. 1632-1642, 2003.